CTRI/2021/04/032863
Completed
未知
Clinical validation study to evaluate the efficacy and safety of unani pharmacopoeical formulation-Qurs-e-Dawa-ul-Shifa in Zightuddam Qawi(Hypertension) - HT
CCRUM0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: I10- Essential (primary) hypertension
- Sponsor
- CCRUM
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Following are inclusion criteria:
- •1 Subjects of either sex in the age group of 18\-65 years.
- •2 Subjects of primary hypertension
- •3 Subjects of Grade\- 1 Hypertension with Systolic BP \[130–139]/ Diastolic BP \[80–89]
- •4 Presence of any of the following symptoms and signs:
- •1 Suda(Headache)
- •2 Duwar(Vertigo)
- •3 Khafaqan(Palpitation)
- •4 Kasal (Laziness)
- •5 Takan(Fatigue)
Exclusion Criteria
- •Patients will be excluded who have any or more of the following conditions:
- •1\.Pregnant and lactating women
- •2\.Chronicity of disease more than 10 years
- •3\.Subjects with SBP \=140 mmHg and Diastolic BP \>90 mmHg
- •4\.Subjects with Secondary Hypertension
- •5\.Subjects taking any other medication affecting blood pressure like NSAIDs and OCPs in females
- •6\.Obese subjects – BMI \>30
- •7\.Systemic diseases requiring long term\-treatment, e.g., DM\-II, Malignancy, Epilepsy, cardiac and kidney diseases.
- •8\.Subjects with Sinus Bradycardia, i.e., pulse rate less than 60/min
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
A confirmatory clinical study of ISN001 in patients with epidermolysis bullosaJPRN-jRCT2033210128Ishiko Akira8
Recruiting
Phase 3
Diferent doses of lactase in subjects with intolerance lactoseRBR-53hjzkutracom Indústria e Comércio Ltda.
Active, not recruiting
Not Applicable
Testing a food supplement in improving strength, power and mental alertnessHealthy volunteerNot ApplicableISRCTN86507492Farmaceutici Procemsa S.p.A.60
Completed
Not Applicable
Clinical study to evaluate the efficacy, pharmacokinetics and safety of immunoglobulin intravenous (human) 10% (NewGam) in patients with primary immunodeficiency diseasesPrimary immunodeficiency diseases (PID)Haematological DisordersCommon variable immunodeficiencyISRCTN05425999Octapharma AG (Switzerland)50
Completed
Phase 2
A Clinical study on cervical spondylosis using thengaai thuruval ottradam (external therapy)Health Condition 1: M478- Other spondylosisCTRI/2021/02/031542Government Siddha medical college and hospital40